Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA

Business Wire March 8, 2022

Revance to Participate in the Cowen 42nd Annual Health Care Conference

Business Wire March 2, 2022

Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

Business Wire February 28, 2022

Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Business Wire February 22, 2022

Deadline Today Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 8, 2022

RVNC Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC

Newsfile February 8, 2022

RVNC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 8, 2022

Newsfile February 8, 2022

RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline TODAY in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Shareholders

PR Newswire February 8, 2022

Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 7, 2022

RVNC Final Deadline Tomorrow: Rosen, Global Investor Counsel, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC

Newsfile February 7, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Revance Investors of a Lead Plaintiff Deadline of February 8, 2022

PR Newswire February 7, 2022

Revance Therapeutics Update

Newsfile February 6, 2022

TUESDAY DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RVNC

Business Wire February 5, 2022

Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Filing Deadline in Class Action Lawsuit

Business Wire February 5, 2022

Revance Therapeutics Class Action Reminder

Newsfile February 5, 2022

REVANCE THERAPEUTICS 96 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC

PR Newswire February 4, 2022

REVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire February 4, 2022

Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Revance Therapeutics, Inc. (RVNC) That a Securities Fraud Class Action Lawsuit Has Been Filed On Their Behalf

PR Newswire February 4, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

PR Newswire February 4, 2022

RVNC 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys, Feb. 8th Deadline in Securities Fraud Suit

Newsfile February 4, 2022